Muna Therapeutics Initiates Phase 1 Trial of Novel Oral TREM2 Agonist MNA-001 for Early Alzheimer's Disease
核心洞察
Muna Therapeutics (搜索) has dosed the first subjects in a Phase 1 trial of MNA-001 (搜索), a novel oral TREM2 (搜索) agonist designed to treat early Alzheimer's disease by enhancing the brain's protective mechanisms.
MNA-001 (搜索) demonstrated best-in-class potential in preclinical studies, significantly reducing amyloid pathology and reprogramming disease-associated microglia to protective states in animal models.
The randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, and pharmacodynamic effects on TREM2 (搜索) biomarkers, with topline data expected by mid-2026.
Muna Therapeutics (搜索) has dosed the first subjects in a Phase 1 clinical trial of MNA-001 (搜索), a novel oral small molecule TREM2 (搜索) agonist designed to treat early Alzheimer's disease. The Copenhagen-based biotechnology company announced this milestone represents its evolution into a clinical-stage organization focused on developing innovative therapeutics for neurodegenerative diseases.
MNA-001 (搜索) represents a paradigm shift in Alzheimer's treatment approach, moving from traditional pathology-clearing strategies to enhancing the brain's innate protective mechanisms. The compound is designed as a potent, selective, orally administered agonist of the triggering receptor expressed on myeloid cells 2 (TREM2 (搜索)), a critical regulator of microglia brain cells with immune and other functions.
Mechanism of Action and Preclinical Evidence
The therapeutic strategy centers on activating TREM2 (搜索) to enhance protective microglial responses to pathology. By boosting TREM2 signaling, MNA-001 (搜索) promotes the phagocytosis of toxic misfolded proteins and cell debris, potentially slowing or stopping neurodegeneration progression.
MNA-001 (搜索)'s best-in-class potential is supported by robust preclinical data demonstrating significant reduction of amyloid pathology and reprogramming of disease-associated microglia to homeostatic, protective states in animal models of Alzheimer's pathology. The molecule demonstrated safety and tolerability in preclinical toxicology studies.
Phase 1 Study Design and Objectives
The single-ascending dose/multiple-ascending dose study is a randomized, double-blind, placebo-controlled trial evaluating MNA-001 (搜索) in healthy adult and elderly participants. The primary objective focuses on assessing safety and tolerability of the investigational compound.
Secondary objectives include evaluating pharmacokinetics and pharmacodynamic effects of MNA-001 (搜索) on biomarkers of TREM2 (搜索) engagement and activation in both plasma and cerebrospinal fluid. The study will leverage Muna's novel biomarker discoveries to provide early insights into MNA-001's activity in humans, with topline data expected in late summer 2026.
Clinical Development Strategy
"We are delighted to have initiated clinical development of MNA-001 (搜索). Our goal is to fundamentally shift the focus in Alzheimer's disease treatment from clearing pathology to bolstering the brain's innate protective mechanisms," said Rita Balice-Gordon, Ph.D., Muna's Chief Executive Officer. "This milestone demonstrates our progress toward advancing disease-modifying therapeutics that mitigate key drivers of neurodegeneration and functional impairment to improve disease outcomes."
Donald Nicholson, Ph.D., Chair of Muna's Board of Directors, emphasized the therapeutic potential: "We believe that MNA-001 (搜索) has the potential to treat disease and improve quality of life for Alzheimer's patients and their loved ones. We intend for this to be the first of several innovative approaches to enhance the brain's resilience to pathological drivers of neurodegeneration."
Company Background and Discovery Platform
Muna Therapeutics (搜索) is pioneering drug discovery for neurodegenerative diseases by focusing on enhancing resilience to misfolded protein pathology effects to protect brain functions like cognition. The company's all-in-human discovery engine identifies new therapeutic targets that can enhance the brain's innate protective mechanisms.
The company name "Muna," meaning "to remember" in Old Norse, reflects its mission to develop a portfolio of therapeutics to slow or stop devastating diseases like Alzheimer's and other neurodegenerative disorders. This Phase 1 initiation represents a significant milestone in the company's clinical development trajectory.